<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282515</url>
  </required_header>
  <id_info>
    <org_study_id>ALH ELP 2/10</org_study_id>
    <nct_id>NCT01282515</nct_id>
  </id_info>
  <brief_title>Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT</brief_title>
  <official_title>A Study of Topical Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) and a Phase III Comparative Treatment Study of HAL PDT in Female Genital Erosive Lichen Planus (GELP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Photocure</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect and side effects of photodynamic treatment and traditional topical&#xD;
      steroid treatment in female genital erosive lichen planus&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the feasibility, efficacy and safety of hexyl 5-aminolevulinate-hydrocloride&#xD;
      (HAL)-PDT in GELP in women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change of GELP score and/or VAS score 6 weeks after start of treatment.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change of GELP score and/or VAS score 6 months after start of treatment.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Genital Lichen Planus</condition>
  <arm_group>
    <arm_group_label>ELP active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one PDT treatment with 2 ml hexaminolevulinate 6 mg/ml gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>topical steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with clobetasol propionate 0.05% ointment used daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clobetasol propionate 0,05% ointment</intervention_name>
    <description>continuously daily treatment for 6 weeks</description>
    <arm_group_label>topical steroids</arm_group_label>
    <other_name>Dermovate 0.05% ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hexaminolevulinate</intervention_name>
    <description>one PDT treatment</description>
    <arm_group_label>ELP active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Women with symptomatically genital ELP, clinically verified by at least one doctor attended&#xD;
        to the Vulva clinic.&#xD;
&#xD;
        Untreated for ELP for at least 4 weeks. Written Informed Consent signed Age 18 or above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Current pelvic inflammatory disease, genital malignancy, or gynecological infection.&#xD;
&#xD;
        Known or suspected porphyria&#xD;
&#xD;
        Known allergy to hexaminolevulinate or similar compounds (e.g. hexaminolevulinate or&#xD;
        aminolevulinic acid) Pregnancy and lactation Participation in other clinical study either&#xD;
        concurrently or within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>anne lise helgesen, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>research fellow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rikshospitalet, OsloUniversity hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>January 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2011</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Anne Lise Helgesen</investigator_full_name>
    <investigator_title>consultant dermatologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

